Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success

 
• By Ayisha Sharma
  
Row of ticks
Galecto's Drug Is First In Class In The Pipeline • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D